CUSIP 00288U106 · who reports it, how much, and how much it matters to them
20 of the 720 hedge fund managers we track reported shares of AbCellera Biologics Inc. (Nasdaq: ABCL) on Form 13F for 30 June 2026. Between them they reported USD 437m. The largest position belongs to Baker Bros. Advisors, at USD 259m. The manager with the most riding on it is Arrowmark Colorado Holdings, where it is 1.3% of the reported book.
Compiled from SEC Form 13F filings · Hedge Fund Intelligence, PPLI.com · updated
Form 13F is filed by the manager and covers all of its accounts, so a position here belongs to the firm, not to any one fund. Not investment advice.
A list of every manager in our coverage that reported this share at the end of the quarter, taken from the filings themselves. Short positions and options are not in it.
Taken from each manager's Form 13F for 30 June 2026. A manager appears here if it reported the shares themselves; positions held only through options are left out.
The bar and the percentage show how much of the manager's reported 13F book the position makes up. Each name opens that manager's largest fund on PPLI.com, where the rest of its book is listed.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Baker Bros. Advisors2 funds on PPLI.com | USD 259m | 1.3% |
| 2 | Two Sigma Investments35 funds on PPLI.com | USD 82m | 0.1% |
| 3 | Arrowmark Colorado Holdings24 funds on PPLI.com | USD 32m | 1.3% |
| 4 | Tudor Investment Corporation10 funds on PPLI.com | USD 16m | 0.0% |
| 5 | Marshall Wace LLP84 funds on PPLI.com | USD 15m | 0.0% |
| 6 | Citadel Advisors32 funds on PPLI.com | USD 12m | 0.0% |
| 7 | Renaissance Technologies13 funds on PPLI.com | USD 7.8m | 0.0% |
| 8 | Millennium Management6 funds on PPLI.com | USD 4.1m | 0.0% |
| 9 | Sculptor Capital67 funds on PPLI.com | USD 3.6m | 0.0% |
| 10 | Exoduspoint Capital Management7 funds on PPLI.com | USD 1.9m | 0.0% |
| 11 | Voloridge Investment Management6 funds on PPLI.com | USD 560,000 | 0.0% |
| 12 | Caxton Associates6 funds on PPLI.com | USD 521,000 | 0.0% |
| 13 | Voleon Capital Management13 funds on PPLI.com | USD 466,000 | 0.0% |
| 14 | D. E. Shaw & Co.15 funds on PPLI.com | USD 357,000 | 0.0% |
| 15 | Oxford Asset Management LLP2 funds on PPLI.com | USD 244,000 | 0.1% |
| 16 | Brandywine Managers47 funds on PPLI.com | USD 224,000 | 0.1% |
| 17 | Brevan Howard Capital Management39 funds on PPLI.com | USD 124,000 | 0.0% |
| 18 | Scientech Research2 funds on PPLI.com | USD 121,000 | 0.1% |
| 19 | Bayforest Capital1 fund on PPLI.com | USD 46,244 | 0.0% |
| 20 | Walleye Capital8 funds on PPLI.com | USD 71 | 0.0% |
A large manager can hold a great deal of a share and barely notice it. This table turns the question round and ranks managers by how much of their own book the position takes up.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Arrowmark Colorado Holdings | USD 32m | 1.3% |
| 2 | Baker Bros. Advisors | USD 259m | 1.3% |
| 3 | Oxford Asset Management LLP | USD 244,000 | 0.1% |
| 4 | Brandywine Managers | USD 224,000 | 0.1% |
| 5 | Scientech Research | USD 121,000 | 0.1% |
| 6 | Two Sigma Investments | USD 82m | 0.1% |
| 7 | Bayforest Capital | USD 46,244 | 0.0% |
| 8 | Sculptor Capital | USD 3.6m | 0.0% |
| 9 | Tudor Investment Corporation | USD 16m | 0.0% |
| 10 | Marshall Wace LLP | USD 15m | 0.0% |
AbCellera Biologics Inc. trades under the symbol ABCL on the Nasdaq. Its CUSIP, the code used on Form 13F, is 00288U106.
20 of the 720 hedge fund managers PPLI.com tracks reported AbCellera Biologics Inc. shares on Form 13F for 30 June 2026. The largest reported positions were held by Baker Bros. Advisors (USD 259m), Two Sigma Investments (USD 82m), Arrowmark Colorado Holdings (USD 32m), Tudor Investment Corporation (USD 16m) and Marshall Wace LLP (USD 15m).
20 managers in our coverage reported it, and between them they run 419 funds with a file on PPLI.com. The count is of managers, because Form 13F is filed by the firm and not by each fund.
Arrowmark Colorado Holdings, where the position was 1.3% of the reported 13F book at 30 June 2026.
No. Form 13F reports long positions in U.S.-listed shares and options. Short positions are not disclosed in it.
Positions are taken by PPLI.com from Form 13F filings with the U.S. Securities and Exchange Commission for the quarter shown. They are reported by each manager, cover all of its accounts and may have changed since. PPLI.com has no relationship with AbCellera Biologics Inc. or with the managers listed.
Nothing here is investment, tax or legal advice, a recommendation, or an offer or solicitation to buy or sell any security. To report an error, write to the editor.
Read our Privacy Policy before submitting. Share only the information needed to describe your question; do not include medical records or account credentials.